Why Staph Aureus Bloodstream Infections Matter

A Serious and Common Infection

Staphylococcus aureus is one of the most common causes of bloodstream infection in hospitals. When the bacteria enter the bloodstream, they can seed infection in the heart valves, bones, joints, lungs, and other organs. This type of infection, called S. aureus bacteremia (SAB), carries substantial risk of death and complications, even with antibiotic treatment.

Why Resistance Makes It Harder

Methicillin-resistant S. aureus (MRSA) does not respond to methicillin, nafcillin, or oxacillin, the standard penicillin-type drugs used against susceptible staph. For decades, clinicians have relied heavily on vancomycin, which must be given by IV infusion and monitored closely because of kidney and drug-level concerns. Other agents, such as daptomycin and linezolid, are used in selected situations. Clinicians have long wanted more options, particularly for patients who cannot tolerate or do not respond to current drugs.

Who Is Most at Risk

People at higher risk include those who have recently been hospitalized, those with IV catheters or other medical devices, people who inject drugs, patients on dialysis, and people with diabetes, heart valve disease, or weakened immune systems. Early, accurate diagnosis and appropriate treatment are central to reducing complications.

Key Takeaways

• Zevtera (ceftobiprole medocaril sodium) received FDA approval on April 3, 2024, for three indications: S. aureus bloodstream infections, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
• The bacteremia approval covers adults with infections caused by both methicillin-susceptible and methicillin-resistant S. aureus, including patients with right-sided infective endocarditis.
• Ceftobiprole is an advanced-generation cephalosporin that binds to penicillin-binding proteins, including PBP2a, the protein that makes MRSA resistant to other beta-lactams.
• In the ERADICATE phase 3 trial, 390 adults were randomized; overall success was 69.8 percent with ceftobiprole and 68.7 percent with daptomycin plus optional aztreonam.
• Zevtera is administered only intravenously and is typically used in hospital or infusion settings.
• Common side effects include nausea, headache, and taste changes. Rash and infusion-related reactions can occur, and anyone with a serious beta-lactam allergy needs careful evaluation first.
• Zevtera is one option among several. Choice depends on susceptibility testing, infection site, kidney function, allergies, and specialist judgment.

What Is Zevtera

Brand and Generic Names

Zevtera is the brand name for ceftobiprole medocaril sodium for injection. The product was developed by Basilea Pharmaceutica, a Swiss biopharmaceutical company. In the United States, it is marketed through Innoviva Specialty Therapeutics. Ceftobiprole medocaril is a prodrug, meaning the body converts it into the active antibiotic, ceftobiprole, after administration.

Drug Class

Ceftobiprole belongs to the cephalosporin family of beta-lactam antibiotics. Earlier cephalosporins were generally ineffective against MRSA. Ceftobiprole is described as an advanced-generation cephalosporin because it was designed to bind the altered penicillin-binding protein that MRSA uses to resist other beta-lactams.

Dosage Form

Zevtera is supplied as a powder in a single-use vial that must be reconstituted and diluted before IV infusion. Because of this preparation step, administration is handled by trained healthcare staff.

FDA Approval: April 3, 2024

The Approval Decision

The FDA approved Zevtera on April 3, 2024. Basilea announced the approval on April 4, 2024, calling it a landmark for ceftobiprole. The sponsor's new drug application had been submitted in 2023, and the FDA accepted it for review that October. The approval package lists three indications, making Zevtera a broad-use product for serious gram-positive infections.

A Long Road to Approval

Ceftobiprole's path to the U.S. market was not short. The FDA issued a complete response letter for an earlier ceftobiprole application in December 2009, which meant more work was needed before approval. Later phase 3 studies, including ERADICATE for bacteremia and TARGET for skin infections, supported the 2024 application.

Pediatric Indication

The approval for community-acquired bacterial pneumonia extends to children aged 3 months and older. The FDA based this decision on the adult CABP trial and a separate pediatric pneumonia study, reflecting the similar course of pneumonia in adults and children.

What the Approval Does Not Mean

FDA approval means the agency reviewed the evidence and found the benefits outweigh the known risks for the approved uses. It does not mean the drug is appropriate for every infection, and it does not mean the drug is first-line for all patients. Labeling defines the approved populations.

How Ceftobiprole Works

Cell Wall Disruption

Like other beta-lactam antibiotics, ceftobiprole kills bacteria by interfering with the construction of their cell walls. It binds to penicillin-binding proteins (PBPs), enzymes bacteria need to cross-link the peptidoglycan that gives the cell wall its strength. When this process fails, the cell wall weakens and the bacterium dies.

The MRSA Problem

MRSA carries a gene (mecA) that produces an altered penicillin-binding protein called PBP2a. PBP2a has low affinity for most beta-lactams, so common drugs fail to shut it down. Ceftobiprole has enough affinity for PBP2a to inhibit it, which is the basis of its anti-MRSA activity.

Why This Matters Clinically

Activity against PBP2a is what separates ceftobiprole from older cephalosporins. In laboratory studies, ceftobiprole also shows activity against some MRSA strains with reduced susceptibility to vancomycin, daptomycin, or linezolid. Laboratory activity does not guarantee clinical success, which is why clinical trials matter.

Activity Against MRSA

In Vitro Evidence

Surveillance studies have tested ceftobiprole against large collections of MRSA isolates from hospitals around the world. A 2025 analysis of MRSA from major pandemic lineages, presented through the SENTRY surveillance program, reflects the ongoing effort to track how well the drug performs against circulating strains. Susceptibility testing in your hospital's lab, not general surveillance, determines whether a particular isolate is treated with ceftobiprole.

Other Gram-Positive Organisms

Ceftobiprole also has activity against methicillin-susceptible S. aureus, coagulase-negative staphylococci, Streptococcus pneumoniae, and several other gram-positive organisms. Gram-negative coverage is also part of its spectrum, which explains why it is used for pneumonia in addition to staph infections.

Limits of the Spectrum

No antibiotic covers every organism. Enterococcus and some resistant gram-negative bacteria may not respond. Susceptibility testing and infectious disease input remain essential.

Approved Uses

S. aureus Bloodstream Infections

Zevtera is approved for adults with S. aureus bacteremia, including those with right-sided infective endocarditis, caused by methicillin-susceptible or methicillin-resistant isolates. This is the most significant indication because bacteremia is serious and treatment options are limited for some patients.

Acute Bacterial Skin and Skin Structure Infections

Zevtera is also approved for adults with ABSSSI, which includes infections such as cellulitis, abscesses with surrounding tissue involvement, and wound infections. The trial supporting this indication compared ceftobiprole with vancomycin plus aztreonam.

Community-Acquired Bacterial Pneumonia

The label includes adults and children aged 3 months and older with CABP. Pneumonia treatment is guided by severity, local resistance patterns, and patient factors, so the decision to use Zevtera for pneumonia rests with the treating clinician.

The ERADICATE Trial

Study Design

ERADICATE was a randomized, controlled, double-blind, multinational phase 3 trial. Participants with S. aureus bacteremia were randomly assigned to receive ceftobiprole or the comparator, daptomycin with optional aztreonam. Blinding and randomization are designed to reduce bias, and multinational enrollment helps show results apply across different care settings.

Who Was Enrolled

The trial enrolled 390 adults. Of these, 192 received ceftobiprole and 198 received the comparator. Patients were typically hospitalized adults with confirmed S. aureus bacteremia, a population similar to the people the approved indication describes.

Primary Endpoint

The primary measure was overall success at a post-treatment evaluation visit about 70 days after randomization. Overall success combined several outcomes: survival, symptom improvement, clearance of bacteremia, no new S. aureus bacteremia complications, and no use of other potentially effective antibiotics. A composite endpoint like this captures whether the infection was truly controlled, not just whether the bacteria disappeared from the blood.

Why the Long Follow-Up

Seventy days is a long follow-up for an antibiotic trial. S. aureus bacteremia can relapse or cause complications weeks after treatment ends, so a short observation window could overstate success. The longer window gives a more complete picture of outcomes.

ERADICATE Results Explained

The Headline Numbers

Overall success was 69.8 percent for ceftobiprole and 68.7 percent for the comparator. The two groups were nearly identical, and the trial was designed to show that ceftobiprole was not meaningfully worse than the comparator. The FDA accepted this non-inferiority-style evidence as supporting approval.

What Non-Inferiority Means

A non-inferiority trial asks whether a new treatment is about as good as an established one, within a pre-set margin. It does not prove the new drug is better. In ERADICATE, the key message is that ceftobiprole performed comparably to daptomycin-based therapy while offering a different option for MRSA infections.

Reading the Numbers Carefully

A composite endpoint with two-thirds of patients reaching overall success means roughly one-third did not. That is consistent with how serious S. aureus bacteremia is. Patients and families should understand that no antibiotic guarantees a cure, and outcomes depend heavily on the source of infection, the presence of heart valve involvement, underlying illness, and how quickly treatment starts.

Limitations to Keep in Mind

Trial populations are carefully selected and may not match every real-world patient. Results also come from a single pivotal study for this indication, and long-term real-world experience is still developing. Clinicians weigh these limits when deciding how to use any new drug.

Skin and Pneumonia Evidence

The TARGET Trial for Skin Infections

The TARGET trial compared ceftobiprole with vancomycin plus aztreonam in acute bacterial skin and skin structure infections. The approval for ABSSSI rests on this randomized, double-blind study. Skin infections are usually treated outpatient or in short hospital stays, and this indication matters most for patients who need an alternative to vancomycin.

Pneumonia Evidence

The CABP indication is supported by an adult pneumonia trial and a separate pediatric study in children from 3 months to under 18 years. The FDA considered the similar clinical course of pneumonia across age groups when extending the indication to children.

Why Multiple Indications Matter

Having approvals across bacteremia, skin infection, and pneumonia gives clinicians more flexibility, but broad labeling also raises stewardship questions. A drug used across many infections can accelerate resistance if used without a clear reason. Careful, targeted use is part of responsible prescribing.

How Zevtera Compares With Other Options

Vancomycin

Vancomycin has been the standard IV therapy for MRSA for decades. It is inexpensive and widely available, but it requires drug-level monitoring, can affect the kidneys, and is less effective than some alternatives for certain MRSA infections. Zevtera offers a different option for some patients, but the choice between them depends on the clinical situation.

Daptomycin

Daptomycin is a lipopeptide antibiotic widely used for MRSA bacteremia. It is the comparator in the ERADICATE trial, and the two drugs performed similarly in overall success. Daptomycin is not used for pneumonia because it is inactivated by lung surfactant, which is one reason Zevtera's pneumonia indication is valuable.

Linezolid

Linezolid is an oral and IV option for many gram-positive infections, including some pneumonia and skin infections. It is generally not used as the main treatment for bloodstream infections because it is bacteriostatic and has risks such as low platelet counts with longer courses. Zevtera is an alternative in situations where linezolid is less suitable.

Other Cephalosporins

Older cephalosporins such as cefazolin are the standard for methicillin-susceptible S. aureus but do not reliably treat MRSA. Zevtera stands apart from them because it targets PBP2a.

Dosing and Administration

General Approach

Zevtera is given intravenously. Dosing depends on the approved indication, kidney function, and the clinical team's plan. Confirm exact dosing and infusion instructions with the current U.S. prescribing information and your care team, because labeling can be updated.

Infusion Process

The powder is reconstituted and diluted according to the label, then given as an infusion over a set period. Nurses and pharmacists handle preparation to ensure accuracy and sterility. Patients should tell staff about any reactions during infusion, such as flushing, rash, or discomfort at the site.

Treatment Duration

Length of therapy varies. Bloodstream infections often require longer courses than skin infections, and complicated cases can require extended treatment. The duration is set by the infection type, the patient's response, and the care team's assessment.

Missed Doses

In a hospital, missed or delayed doses are handled by nursing and pharmacy staff. Patients receiving home infusion should contact their provider if a dose is missed rather than doubling up later.

Kidney Function and Dosing

Why Kidney Function Matters

Ceftobiprole is cleared by the kidneys, so reduced kidney function can cause the drug to build up. Your care team should check kidney function before starting treatment and monitor it during therapy, especially in older adults, people with existing kidney disease, and those receiving other nephrotoxic drugs.

Dialysis Patients

People on dialysis need individualized dosing plans developed with the nephrology and pharmacy team. Bloodstream infections are common in dialysis patients, so this group is an important part of the treatment population.

Adjustments

Labeling provides guidance for adjusting doses in renal impairment. Do not adjust doses on your own. Your team will use current labeling and your lab results to decide what is appropriate.

Common Side Effects

Gastrointestinal Effects

Nausea and diarrhea are among the more frequently reported side effects of cephalosporins. Most are mild and manageable. Tell your care team if diarrhea is persistent, watery, or bloody, because Clostridioides difficile infection can occur with almost any antibiotic.

Headache and Taste Changes

Headache and changes in taste have been reported with ceftobiprole in clinical use. These effects are usually mild, but they should still be mentioned to your team.

Infusion-Site Reactions

Pain, redness, or swelling where the IV line is placed can happen. Good line care and rotating sites reduce the risk. Report any unusual swelling or pain promptly.

Rash

Skin rash can occur. Mild rash may be monitored, but a rash with fever, blistering, mouth sores, or swelling of the face or throat needs urgent medical attention.

Serious Risks and Warnings

Allergic Reactions

Serious allergic reactions, including anaphylaxis, are possible with any beta-lactam antibiotic. Symptoms include hives, throat tightness, trouble breathing, dizziness, or fainting. These reactions require emergency treatment, and patients should tell staff about any past reactions to penicillins or cephalosporins before the first dose.

Clostridioides difficile Infection

C. difficile can cause severe diarrhea and colitis, sometimes after antibiotic exposure. Any new or worsening diarrhea during or after treatment should be reported. Treatment for C. difficile differs from antibiotic treatment for other infections, so early evaluation matters.

Seizures and Neurologic Effects

Certain beta-lactam antibiotics can cause neurologic side effects, especially in people with kidney impairment or existing seizure disorders. Clinicians monitor for confusion, unusual movements, or changes in alertness during treatment.

Blood Count Changes

Cephalosporins can occasionally lower white blood cell or platelet counts. Routine blood tests during a hospital course help detect these changes early.

Liver Function

Liver enzyme elevations can occur with antibiotic therapy. Monitoring liver tests is appropriate for patients with liver disease or those on long courses.

Who Should Not Receive Zevtera

Known Allergy

Anyone with a known allergy to ceftobiprole, other cephalosporins, or any ingredient in the formulation should not receive Zevtera. Your care team will review your allergy history before treatment.

Beta-Lactam Allergy History

People with a history of severe penicillin reactions need individualized assessment. Cross-reactivity between beta-lactam classes is uncommon but not impossible, and the decision depends on the nature of the past reaction.

Other Considerations

Your clinician will consider kidney function, pregnancy status, other medications, and the specific infection before choosing Zevtera. Some patients may be better served by other antibiotics, and that is a normal part of treatment planning.

Drug Interactions

Medication Review

Give your care team a complete list of medications, including prescriptions, over-the-counter products, and supplements. Pharmacists check for interactions before starting any new antibiotic.

Anticoagulants

Some antibiotics can affect how blood thinners work. If you take warfarin or another anticoagulant, your team may check clotting tests more often during treatment.

Probenecid

Probenecid can slow kidney elimination of some beta-lactam antibiotics. Your pharmacist will check whether this matters for your regimen.

Pregnancy, Breastfeeding, and Children

Pregnancy

Zevtera should be used in pregnancy only when the benefit justifies the risk. Pregnant patients should discuss treatment options with their obstetric and infectious disease teams, because untreated S. aureus bloodstream infection is dangerous for both mother and baby.

Breastfeeding

Cephalosporins pass into breast milk in small amounts. Discuss breastfeeding plans with your care team so they can weigh the benefits and any infant considerations.

Children

The label includes children aged 3 months and older for community-acquired pneumonia. Use in children for other indications should follow the labeling and specialist guidance. Pediatric dosing is always weight- and age-based and set by the pediatric team.

Antibiotic Stewardship and Resistance

Why Stewardship Matters

Every antibiotic creates selection pressure for resistance. New drugs are valuable only if they are used wisely. Hospitals use stewardship programs to ensure that antibiotics such as Zevtera are chosen based on cultures, susceptibility results, and clinical need.

Culture Before Treatment

Blood cultures should be drawn before antibiotics whenever possible. Confirming the organism and its susceptibility pattern guides therapy and can allow clinicians to narrow treatment or switch agents when appropriate.

Resistance Monitoring

Because ceftobiprole is new to routine U.S. practice, ongoing surveillance will show how resistance patterns develop. Clinicians and laboratories report unusual resistance findings to public health authorities.

Availability and Cost

Availability

Innoviva Specialty Therapeutics announced that Zevtera became commercially available in the United States after approval. Hospitals and specialty pharmacies stock the drug as needed. Availability can vary by facility, so your care team will confirm what is available.

Cost

Pricing for hospital IV antibiotics is complex and often bundled into the overall hospital stay. Out-of-pocket costs depend on insurance, plan coverage, and whether the drug is given inpatient or at home. Ask your insurer or hospital financial counselor for specifics. Pricing details may change, so verify current figures directly.

Insurance Coverage

Coverage for FDA-approved indications is generally more straightforward than off-label use, but prior authorization may be required. Your care team's pharmacy staff can help with approvals.

Questions to Ask Your Care Team

• Is my infection confirmed by blood culture, and what bacteria were identified?
• Is the organism susceptible to ceftobiprole, and what other options exist?
• Do I need an echocardiogram to check my heart valves?
• How will my kidney function be monitored during treatment?
• What side effects should I report right away?
• How long will I need treatment, and will I need IV access at home?
• Are there any interactions with my current medications?

Frequently Asked Questions

Q: What is Zevtera used for?

A: Zevtera is approved for adults with S. aureus bloodstream infections (including right-sided endocarditis), adults with acute bacterial skin infections, and adults and children aged 3 months and older with community-acquired pneumonia.

Q: Does Zevtera treat MRSA?

A: Yes. The bacteremia approval covers both methicillin-susceptible and methicillin-resistant S. aureus.

Q: How well did it work in the main trial?

A: In the ERADICATE trial, overall success was 69.8 percent with ceftobiprole and 68.7 percent with daptomycin plus optional aztreonam. Overall success was a composite that included survival and clearance of the infection.

Q: Is Zevtera a pill?

A: No. It is given only by IV infusion.

Q: Can I receive Zevtera if I'm allergic to penicillin?

A: Possibly, but this requires careful review. Tell your care team about the type of reaction you had so they can assess cross-reactivity risk.

Q: Is Zevtera better than vancomycin?

A: Neither is universally better. The right choice depends on the infection, susceptibility results, kidney function, and clinical judgment. Your infectious disease team will make this decision with you.

Q: What should I do if I have diarrhea during treatment?

A: Tell your care team promptly. Persistent or bloody diarrhea needs evaluation, including testing for C. difficile.

Medical Disclaimer

This article is for general education only and does not provide medical advice, diagnosis, or treatment. Staphylococcus aureus bloodstream infections are serious and require hospital-based evaluation. Do not start, stop, or change any antibiotic without guidance from a licensed clinician. For dosing, interactions, and safety information, consult the current U.S. prescribing information and your healthcare team. If you have symptoms of a serious infection, such as fever with chills, rapid heartbeat, confusion, or difficulty breathing, seek emergency care immediately.

Sources and Further Reading

• U.S. FDA Approval Package for Zevtera (ceftobiprole medocaril sodium for injection), NDA 218275, approval date April 3, 2024
• FDA press announcement: "FDA Approves New Antibiotic for Three Different Uses," April 3, 2024
• Basilea Pharmaceutica press release on U.S. FDA approval of ZEVTERA, April 4, 2024
• Holland et al., ERADICATE phase 3 trial of ceftobiprole in S. aureus bacteremia, New England Journal of Medicine, 2023
• Drugs.com Zevtera FDA approval history and development timeline
• Innoviva Specialty Therapeutics announcement of commercial availability of Zevtera in the United States
• SENTRY surveillance analyses of ceftobiprole activity against MRSA (2025)
• Pharmacokinetic-pharmacodynamic analyses supporting ceftobiprole dosing in S. aureus bacteremia (2026 abstract)

This article reflects information available as of October 2026. Check the current prescribing information and your healthcare provider for the latest guidance. For more on antibiotic options, visit MyOnlineMedShop blog or contact us.